A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Unknown

Federal Circuit Flas

By Ken Winterbottom J.P. Morgan Appeal Dismissed for Lack of Jurisdiction In ...

Photo By: darkuncle - CC BY 2.0

Pass the Patented Pe

  [caption id="attachment_3359" align="alignleft" width="150"] Photo By: darkuncle - CC BY ...

th

Stephen Hawking™:

By Amanda Liverzani – Edited by Saukshmya Trichi Application Stephen Hawking is ...

Unknown

Flash Digest: News i

By Jeanne Jeong European Regulators and Watchdogs Increase Investigation of “Technology ...

1000

Australian Parliamen

By Jenny Choi – Edited by Katherine Kwong Telecommunications (Interception and ...